Claims Scope:

Patent issued December 5, 2017. 

≥85% Sequence Identity – Methods only 

Methods of treating cancer with compositions of viral vectors comprising shRNA or miRNA capable of inhibiting the mevalonate pathway with shRNA having at least 85% percent identity to SEQ 1-4, or, microRNA having at least 85% identity to SEQ 5-10.